TRAVOPROST S.K.

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

TRAVOPROST

Disponibbli minn:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

Kodiċi ATC:

S01EE04

Għamla farmaċewtika:

OPHTHALMIC SOLUTION

Kompożizzjoni:

TRAVOPROST 0.04 MG/ML

Rotta amministrattiva:

OCULAR

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

RAFARM S.A., GREECE

Żona terapewtika:

TRAVOPROST

Indikazzjonijiet terapewtiċi:

For the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another IOP lowering medication

Data ta 'l-awtorizzazzjoni:

2019-05-30

Fuljett ta 'informazzjoni

PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS REGULATIONS
(PREPARATIONS)
- 1986
The medication is marketed by doctor’s prescription only
TRAVOPROST S.K.
Eye drops (solution)
Active ingredient: Travoprost 40mcg/ml
Inactive ingredients in the preparation are listed in the
“Additional Information”
chapter at the end of the leaflet (Section 6).
READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE
MEDICATION.
This leaflet contains concise information on the medication. If you
have further
questions, refer to the doctor or pharmacist. This medication was
prescribed for the
treatment of your disease. Do not pass it on to others. It might harm
them even if it
seems to you that their medical condition is similar.
1. WHAT IS THIS MEDICATION INTENDED FOR?
MEDICAL ACTIVITY:
The medication is intended to reduce intraocular pressure in patients
with open-angle
glaucoma or patients who are insufficiently responsive to other drugs
intended for the
same purpose.
THERAPEUTIC GROUP:
Prostaglandin analog
2. BEFORE USING THE MEDICATION
DO NOT USE THE MEDICATION IF:
∙ You are pregnant, breastfeeding or while undergoing a fertility
treatment.
∙You have a known sensitivity to any of the ingredients in the
medicine.
WARNINGS
∙The medicine is not intended for children.
∙A change in the color of the iris may occur during treatment. There
may also be
effects of lengthening of eyelashes, and/or change in their color,
thickening of
eyelashes and/or change in the number of eyelashes, unusual growth of
eyelid hair.
These changes might sometimes be permanent.
∙ In rare cases, shortness of breath, wheezing, increased asthma
symptoms may
develop. If you are concerned about changes in your breathing, consult
a doctor.
∙ The medicine may be absorbed through the skin. If the preparation
comes in
contact with the skin, wash immediately, especially in pregnant women
or in women
who are trying to conceive.
∙ If you underwent a cataract surgery, inform the doctor before
starting to use the
medicine.
∙ If you have suffered